Skip to main content

Table 3A Immunological and clinical response in patients vaccinated with iDC

From: Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

Patient ID No. of Vaccinations Antigens (Type of Lysate) Median No. of Administered Cells × 106(range) DTH Best Response after 4 or More Vaccinations. Vitiligo Clinical Response Response Duration (Months) Overall Survival (Months)
     L/H KLH     
1 L.A. 8 H 49.5 (15 – 82) + +   SD 6 45
2 G.I. 5 L 13 (4.5 – 26) - +   SD 6 26
3 M.G. 5 L 11 (7 – 16.2) - - +/- SD 6 7
4 S.P. 8 L 26.5 (10 – 43.5) - -   PD - 8
5 G.C. 6 L 19 (9.6 – 32) - -   PD - 10
6 Z.V. 5 L/H 11.3 (6.4 – 21.5) - -   PD - 4
7 G.L. 6 H 22.6 (16.4 – 48) - -   PD - 5
8 B.A. 4 H 15 (12 – 51) - -   PD - 5
No. of Patients Administration Route Site No. of Inoculations       
8 iDC 4 i.d. and 4 s.c. 6 inguinal and 2 axillary 6–8       
  1. DTH, delayed-type hypersensitivity; L, autologus lysate; H, autologous homogenate; KLH, keyhole limpet hemocyanin; SD, stabilization; PD, progressive disease.
  2. i.d., intradermal; s.c., subcutaneous